English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Treatment-free remission is achievable in approximately half of patients with chronic myeloid leukemia who attain a sustained, deep molecular response with tyrosine-kinase inhibitor (TKI) therapy. We aimed to identify potential predictors of future achievement of stable MR 4.5 , defined as a sustained 4.5-log reduction in  BCR-ABL1  transcripts for a minimum of 2 years, in 593 patients treated with imatinib as first-line TKI therapy. In multivariable analyses of patient and disease variables including baseline blood counts, disease phase, additional cytogenetic abnormalities, prior therapy, depth and rapidity of molecular response, the only predictor for future achievement of stable MR 4.5  was molecular response at 6 months. In this study, patients failing to attain a molecular response of  BCR-ABL1 ≤ 0.16% IS  after 6 months of imatinib therapy were unlikely to subsequently achieve stable MR 4.5  with imatinib. Our data suggest that achievement of  BCR-ABL1 ≤ 0.16% IS  at 6 months is predictive of future stable MR 4.5 .

leukemia and lymphoma

Early prediction of stable MR 4.5  by depth of molecular response at 6 months in patients with chronic myeloid leukemia treated with frontline imatinib